‘Much-needed hope’ as CRISPR gene editing therapy recommended for sickle cell disease
Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant access to gene-editing therapy on the NHS. View on euronews
Groundbreaking one-off gene therapy approved for severe sickle cell disease
People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) to allow patients with sickle cell disease (SCD) to access its gene-edited therapy Casgevy,
£1.65m gene-editing therapy offers hope of cure for some blood disorder patients
A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder hope of a cure. Campaigners reacted with joy as health officials approved a gene-editing therapy for certain children and adults with severe sickle cell disorder.
Sickle cell gene therapy Casgevy finally cleared for NHS use
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme and with a confidential discount.
New Base Editing Gene Therapy Cures its First Patient: A Sickle-Cell Sufferer Now in the ‘Gym Every Day’
Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.
'Will it really work?': Young sickle cell patient among the first to start new gene therapy
Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the multimillion dollar, medically-intensive therapies.
‘Ground-breaking’ gene treatment for sickle cell disease to be rolled out on NHS
A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off treatment costs more than £1million per patient but may essentially
NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease
The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) gene therapy to treat a severe form of sickle cell disease (SCD).
UK health system to offer cutting-edge gene therapy for sickle cell disease
The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and then infusing them back into the patient.
NHS to offer 'groundbreaking' sickle cell gene therapy
The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts say.
Gene Therapy Market Size is Expected to Reach USD 29.24 Billion by 2033, Growing at a CAGR of 18.60%: Straits Research
The global gene therapy market size was valued at USD 6.30 billion in 2024 and is projected to reach from USD 7.47 billion in ...
Genetic Swiss Army Knife: New Tool For Gene Editing And Therapy
This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...